Screening and Identification of Human Urate Transporter hURAT1 MicroRNA

Urinary Calculi Clinical Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01973088
• Other study ID #: Southwest Hospital,TMMU
• Status: Active, not recruiting
• Phase: N/A
• First received: October 20, 2013
• Last updated: December 8, 2013
• Start date: November 2013

Study information

• Verified date: September 2013
• Source: Southwest Hospital, China
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Ethics Committee
• Study type: Observational

Clinical Trial Summary

This study intends to use in patients with renal tissue and blood samples, screening and identification of renal tissue hURAT1 regulating the expression of micro-RNA, for further study of uric acid stone formation mechanism and the occurrence of clinical preventive uric acid stones provide new clues and new intervention targets.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 80
• Est. primary completion date: June 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

A?B group were enrolled standards: ? aged 18-65 years old; ? comply with percutaneous nephrolithotomy lithotripsy indications for surgery; ? ECT tips ipsilateral normal or mildly impaired renal function.

Group C patients were enrolled standards: ? aged 18-65 years old; ? normal renal function, not associated with urinary calculi in patients; ? cancer patients met radical nephrectomy indications for surgery; ? emergency trauma patients suffering from kidney resection surgical indications.

Exclusion Criteria:

• aged <18 years or> 65 years; ? neurological disease or cognitive dysfunction; ? can not be corrected or uncorrected coagulopathy; ? associated with diabetes, hypertension and other metabolic diseases; ? accompanied by tuberculosis, hepatitis, HIV and other infectious diseases; ? poor tolerance to anesthesia and surgery, such as: severe cardiopulmonary disease, coagulation disorders, etc.; ? ultrasound, renal imaging examination revealed renal cortex was significantly thinner (renal cortical thickness <1.5cm), structural variation; ? with severe systemic or urinary tract infection; ? ECT tips ipsilateral renal function is severely impaired or solitary kidney.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Urinary Calculi

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Qian-wei Li

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	micro-RNA	microRNA microarray:the micro-RNA of kidney tissue	6 months	No
Secondary	Urine	Urine Analyzer:Urine color, transparency, pH, erythrocytes, leukocytes, epithelial cells, casts, protein, specific gravity, and qualitative urine	24 hours	No
Secondary	24h urine quantitative analysis	Urine Analyzer:Urine, sodium, potassium, calcium, magnesium, ammonium, phosphate, sulfate, uric acid, oxalate, citrate, creatinine	96 hours	No
Secondary	Blood biochemistry	Blood biochemical analyzer:Sodium, potassium, chloride, calcium, phosphorus, magnesium, bicarbonate, uric acid, creatinine	24 hours	No
Secondary	Stone analysis	Infrared Spectroscopy:Calcium oxalate monohydrate , carbonated apatite, calcium oxalate dihydrate ,anhydrous uric acid, urine ammonium,magnesium ammonium phosphate	3 weeks	No
Secondary	hURAT1 transporter protein	WESTERN BLOT?RT-qPCR:hURAT1 transporter protein of kidney tissue	6 months	No